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782Strong Association between Respiratory Viral Infection
Early after Hematopoietic Stem Cell Transplantation
and the Development of Life-Threatening Acute and
Chronic Alloimmune Lung Syndromes
A. Birgitta Versluys,1 John W. A. Rossen,2,3 Bart van Ewijk,4 Rob Schuurman,2
Marc B. Bierings,1 Jaap J. Boelens1Alloimmune lung syndromes (allo-LS), including idiopathic pneumonia syndrome, bronchiolitis obliterans
syndrome, and bronchiolitis obliterans organizing pneumonia, are severe complications after hematopoietic
stem cell transplantation (HSCT). In our cohort of 110 pediatric patients, 30 had allo-LS (27.3%), 18 with
ideopathic pneumonia syndrome and 12 with bronchiolitis obliterans syndrome. Multivariate analysis
showed that respiratory viral infection early after HSCT is an important predictor for the development of
allo-LS (P\.0001). This was true for all viruses tested. In multivariate analysis, allo-LS was the only predictor
for higher mortality (P5.04). Paradoxically, prolonged administration of immunosuppressive agents because
of acute graft-versus-host disease had a protective effect on the development of allo-LS (P 5 .004). We hy-
pothesize that early infection of the respiratory tract with a common cold virus makes the lungs a target for
alloimmunity.
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Pulmonary complications are common after alloge-
neic hematopoietic stem cell transplantation (HSCT).
Between30%and60%ofadultHSCTrecipients report-
edly experience pulmonary complications, representing
a major cause of mortality [1-4]. In children undergoing
HSCT, the incidence of pulmonary complications varies1Department of Pediatric Hematology/Immunology and
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6/j.bbmt.2009.12.534from 10% to 25%, and onset is a poor prognostic event
carrying a significantly increased risk of mortality
[5,6]. At one time, most pulmonary complications were
directly related to infection; today, however, noninfec-
tious pulmonary complications, such as idiopathic pneu-
monia syndrome (IPS) and bronchiolitis obliterans
syndrome (BOS), are seen more frequently [2,5,6].
Respiratory virus (RV) infections occur in 1%-
56% of HSCT recipients. Most previous studies
have examined the progression from upper respiratory
tract infection (URTI) to lower respiratory tract infec-
tion (LRTI) and described the risk factors for this pro-
gression [7-16]. Some have reported an association of
early RV infection with late, obstructive lung injury
[17]. An association between RV infection and alloim-
munity in lung transplant recipients was recently re-
ported [18]. Lung transplant recipients develop more
acute and chronic graft rejection after common RV
infection early (\100 days) after transplantation [18].
Isolated alloimmune lung disease (ie, BOS or IPS)
after HSCT suggests a specific trigger making the lung
a target organ for alloreactivity. This is in line with the
3-step process reflecting the current view of the devel-
opment of alloreactivity: (1) tissue damage, resulting in
(2) release of inflammatory cytokines, resulting in (3)
activation and influx of T lymphocytes [19]. We
speculated that the presence of a common RV might
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HSCT. We prospectively studied the influence of
these RVs on the development of allo-LS and overall
survival (OS) in a cohort of pediatric HSCT recipients.PATIENTS AND METHODS
Study Design and Study Populations
All patients who underwent allogeneic HSCT
between January 2004 and May 2008 at the pediatric
Hematology and Immunology Department of the
Wilhelmina Children’s Hospital/University Medical
Center were included in this prospective study.
Patients were enrolled in the HSCT protocol after
providing written informed consent for the HSCT
and the research protocol.
Supportive Care and Graft-versus-Host Disease
Prophylaxis
All patients received antiemetic drugs. Prophylactic
anticonvulsive therapy (clonazepam) was given to those
patients receiving busulfan. Antibiotic prophylaxis in-
volved daily ciprofloxacillin and fluconazole from the
start of conditioning until the resolution of neutropenia
(3 days of .500,000 neutrophils/mL). Additional pro-
phylaxis against Streptococcus viridans in the mucositis
phase was given with cefazoline. Starting 1 month after
transplantation, cotrimoxazole 3 times a week was given
as Pneumocystis carinii pneumonia prophylaxis. Only in
cases of positive serology for herpes simplex virus was
prophylaxis (with acyclovir) administered. No prophy-
laxis for other viruses was given. IgG levels were checked
every 2 weeks; intravenous immunoglobulin was given
only to those patients with an IgG level\4 g/L.
Graft-versus-host disease (GVHD) prophylaxis
consisted of cyclosporine (aiming for a trough level of
100-250 mg/L, based on national protocol guidelines),
supplemented with methylprednisolone (MP; 1 mg/
kg/day for 28 days) in patients receiving a cord blood
(CB) transplant, or methotrexate (short course, 10 mg/
m2 on days 1, 3, and 6) in patients receiving an unrelated
bone marrow (BM) or peripheral blood stem cell
(PBSC) transplant. In patients receiving an unrelated
donor graft (CB, BM, or PBSC), antithymocyte globu-
lin (ATG) serotherapy was administered until day –1,
with ATG-fresenius for patients with acute lymphoblas-
tic leukemia and thymoglobulin for all other indications.
Infection Monitoring
Bacterial/Fungal
To monitor bacterial colonization, nose/throat
swabs and stools were cultured weekly and processed
in accordance with standard microbiological proce-
dures. Up to June 2006, we tested for galactomannan
(Platelia Aspergillus enzyme immunoassay; Bio-Rad,Hercules, CA) in cases of suspected Aspergillus infec-
tion, based on such clinical symptoms as prolonged
fever during systemic broad antibiotic therapy and
radiologic findings. After June 2006, we routinely
monitored galactomannan twice weekly.
Viral
Plasma was tested weekly for Epstein-Barr virus
(EBV), cytomegalovirus (CMV), human herpes 6 virus
(HHV6), and adenovirus DNA positivity by real-time
polymerase chain reaction (PCR) (see next section). In
patients deemed positive (viral load .400 cp/mL),
this test was done twice a week. Adenovirus (viral load
.1000 cp/mL)was treated preemptivelywith cidofovir.
CMV (viral load .1000 cp/mL) was treated preemp-
tively with foscavir or ganciclovir. Depending on the vi-
ral load, the immunosuppressive regimen, and signs of
posttransplantation lymphoproliferative disease, EBV
was treated preemptively with anti-CD20 (rituximab).
Respiratory Viral
Before August 2005, nasal pharyngeal aspirate
(NPA) samples were obtained for PCR only in the pres-
ence of symptoms of a URTI or LRTI, and then only up
to day1100 posttransplantation. FromAugust 2005 on-
ward,we performed surveillance studies onNPA samples
of all patients admitted to our HSCT unit. Reverse-
transcriptase (RT)-PCR was done for all common RVs
(see later).We repeated theNPAweekly in patients neg-
ative for RV and twice weekly in patients positive for RV.Real-Time PCR for Respiratory Viruses
Nucleic acids were extracted using the total nucleic
acid protocol with the MagNA Pure LC nucleic acid
isolation system (Roche Diagnostics, Basel, Switzer-
land). For detection of RNA viruses, cDNA was syn-
thesized using MultiScribe RT and random hexamers
(Applied Biosystems, Foster City, CA). Detection of
viral and atypical pathogens was performed in parallel,
using real-time PCR assays specific for the following
viruses: CMV; EBV; HHV-6; respiratory syncytial vi-
rus A and B; influenzavirus A and B; parainfluenzavirus
1-4; rhinoviruses; adenoviruses; human coronaviruses
OC43, NL63, and 229E; human metapneumovirus;
Mycoplasma pneumoniae; and Chlamydia pneumoniae.
Real-time PCR procedures were performed as de-
scribed previously [20]. In brief, samples were assayed
in duplicate in a 25-mL reaction mixture containing 10
mL of cDNA, 12.5 mL of TaqMan Universal PCR
Master Mix (Applied Biosystems), 300-900 nmol/L
of the forward and reverse primers, and 75-200
nmol/L of each probe. All samples had been spiked be-
fore extraction with an internal control virus (murine
encephalomyocarditis virus [RNA virus] and porcine
herpesvirus [DNA virus]) to monitor for efficient
extraction and amplification, essentially as described
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impression of the quantity of the viral load (ie, a semi-
quantitative value).
Recording Pulmonary Complications
All patients were observed for signs of respiratory
disease early and late after transplantation. All clinical
symptoms were recorded. In patients with URTI
symptoms, NPA samples were obtained and tested
for RV infection by PCR (see earlier). In patients
with signs of LRTI, chest X-rays were obtained. Other
tests, performed as indicated, included bronchoalveo-
lar lavage (BAL) for broad infectious screening with
bacterial/fungal cultures, viral PCR, and galacto-
mannan, as well as high-resolution computed tomog-
raphy (HRCT) scans. In cases of suspected allo-LS,
HRCT and BAL were always performed (see defini-
tions of disease shortly).
Pulmonary Function Tests
Because performing pulmonary function tests
(PFTs) is difficult in young children, in our cohort rou-
tine PFTs before transplantation were performed only
in children aged$6 years. PFTs also were performed in
all children with such respiratory symptoms as short-
ness of breath, dry cough, and tachypnea after dis-
charge. In patients with a diagnosis of allo-LS, PFTs
were repeated at least monthly until the disorder re-
solved. Patients aged $6 years underwent spirometry
testing and, when technically possible, body plethys-
mography and CO diffusion testing according to Euro-
pean Respiratory Society guidelines [22]. Total lung
capacity (TLC) and forced expiratory volume in 1 sec-
ond (FEV1) were expressed as percentage of the pre-
dicted normal value, using published equations for
children and adults [23], giving TLC % predicted and
FEV1 % predicted. A TLC % predicted of \80%
was designated a ‘‘restrictive’’ pattern; an FEV1 % pre-
dicted of\80% and FEV1/forced vital capacity (FVC)
of\70%, an ‘‘obstructive’’ pattern; a TLC%predicted
of\80% and FEV1/FVC of\70%, a ‘‘mixed’’ pattern;
and CO diffusion of\80%, ‘‘impaired diffusion.’’
Definitions of Disease
URTI was defined as rhinorrhea and/or dry cough
only. LRTI/pneumonia was defined as cough and/or
fever and pulmonary infiltrates on chest x-ray, with
elevated C-reactive protein and/or positive microbio-
logical cultures from sputum, BAL fluid, or blood.
IPS was defined as the presence of acute bilateral
pulmonary infiltrates with cough, dyspnea, and hypox-
emia in the absence of infection (excluding an RV) or
heart failure. By this definition, IPS included such
entities as diffuse alveolar bleeding and periengraft-
ment syndrome [2]. BOS was defined as typical
HRCT changes, such as bronchial wall thickening,air trapping, and mosaic parenchymal attenuation
[1], in the absence of signs of infection and, whenever
pulmonary function testing could be done, abnormal
pulmonary function test results (ie, decrease in FEV1
of .20% or in FEV1/FVC of \70%). bronchiolitis
obliterans organizing pneumonia (BOOP) was defined
as restrictive PFT (if PFT were done) and consolida-
tion on chest x-ray [1]. Allo-LS was defined as IPS,
BOS, and BOOP, subdivided into acute (IPS) and
chronic (BOS/BOOP) forms.
Treatment of Lung Disease
In general, URTI was not treated; only in the 2 pa-
tients with influenza A was a neuraminidase inhibitor
administered. LRTI/pneumonia was treated with em-
piric antibiotic therapy (vancomycin and ceftazidime).
Whenever a bacterial pathogen was found, therapy was
adjusted according to antibiotic resistance. In patients
with probable or proven Aspergillus spp, voriconazole
was administered; if no response to voriconazole was
noted (progressive clinical or radiologic findings),
granulocyte transfusions were given.
Allo-LS was treated withMP 10 mg/kg/day i.v. for
3 days and 2 mg/kg/day thereafter, tapering by 25%
per week to 0.5 mg/kg/day. The MP pulses were re-
peated every 4 weeks until recovery, up to a maximum
of 6 courses. Recovery was defined as normalization of
PFTs and/or resolved symptoms, with no extra oxygen
requirement. In between the subsequent courses of
MP, prednisone 0.5 mg/kg/day was given. Other im-
munosuppressive agents (usually cyclosporine) were
continued. In addition, azythromycin was given, be-
cause of its suggested immunomodulatory effect [24].
Along with immunosuppressive therapy, supportive
care was provided, with extra oxygen and mechanical
ventilation when necessary. IgG level was maintained
above 4 g/L.
Endpoints
The primary endpoint of this study was the devel-
opment of acute and chronic allo-LS. The secondary
endpoint was OS.
Statistical Analysis
Differences between the RV-positive and RV-
negative groups were tested using Pearson’s c2 test.
Results with a P value\.05 were considered statisti-
cally significant.
The duration of follow-up was the time to the end-
points, the development of an allo-LS and death, or the
last assessment for survivors. To analyze risk factors
for outcomes, we considered variables associated
with the recipient (age at transplantation, sex, CMV
serology, RV positivity, single/multiple viruses), the
disease (malignant vs nonmalignant), the donor/trans-
plantation technique (cell source, HLA disparity,
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complications (allo-LS, acute GVHD [aGVHD],
CMV and adenovirus plasma DNA positivity, veno-
occlusive disease), and relapse. To examine the influ-
ence of the various viruses on the primary endpoint,
rhinovirus was compared with the other viruses, and
multiple viral infection was compared with single viral
infection.
In the analyses, we tested for allo-LS as a group
(IPS 1 BOS/BOOP) based on the hypothesis that
early viral infection might be a trigger for both acute
and chronic allo-LS. In addition, we tested both syn-
dromes separately (ie, BOS/BOOP excluding IPS
from the analyses, and IPS excluding BOS/BOOP).
Associations between variables (including recipi-
ent, disease, and HSCT technique) and the primary
endpoint were evaluated using Cox proportional haz-
ard models. Dichotomous outcomes (eg, allo-LS:
yes/no) were used as dependent variables, and predic-
tors were used as independent variables. Univariate
predictors of outcome with a P value\.10 were used
for multivariate analysis. Results are expressed as haz-
ard ratios (HRs) and corresponding 95% confidence
interval (CIs). CIs not including 1 were considered sta-
tistically significant.
Analyses for the association between HSCT com-
plications and the primary endpoint (allo-LS) as well as
the secondary endpoint (OS) were done using logistic
regression. Dichotomous outcomes (eg, allo-LS or
survival: yes/no) were used as dependent variables,
and predictors were used as independent variables.
Univariate predictors of outcome with a P value
\.10 were used for multivariate logistic regression
analysis. Results are expressed as odds ratio (ORs)
and corresponding 95% CIs. CIs not including 1
were considered statistically significant.
Probabilities of allo-LS andOSwere calculated using
the Kaplan-Meier estimate; the 2-sided log-rank test
was used for comparisons. All statistical analyses were
performed using SPSS 15.1 (SPSS Inc, Chicago, IL).RESULTS
Patient Characteristics
A total of 110 patients were included in the study,
42 from January 2004 to August 2006 (before routine
NPA testing), and 68 after from August 2006 to May
2008. Six patients who underwent transplantation dur-
ing this period were excluded from the study because
they experienced autologous recovery (n 5 2), early
graft rejection (within 1 month after transplantation;
n 5 2), or early death (before engraftment; n 5 2)
and thus were considered not prone to alloreactive dis-
ease. The median age at transplantation was 5.0 years
(range, 2 months to 21 years), and body weight ranged
between 2 and 100 kg. Baseline characteristics of theRV-positive and RV-negative groups are shown in
Table 1. No significant differences between the 2
groups were evident, although there were slightly
more matched donor transplants in the RV-negative
group and more CB donors in the RV-positive group.
RV Infections and Presenting Symptoms
In this cohort of patients, 55 (50%) had an RV in-
fection. The median day of onset was day 116 post-
transplantation (range, day 27 to day 1100).
Symptoms were usually mild. The majority of patients
with RV infection (n5 43) had URTI symptoms only.
Eleven patients required extra oxygen, and 1 patient
needed ventilator support (associated with a bacterial
infection). Two patients, both with influenza A infec-
tion, were treated with a neuraminidase inhibitor; all
other patients experienced spontaneous clinical recov-
ery within 7-14 days. Although symptoms disappeared,
virus was detected inNPA samples for weeks tomonths
afterward, with high viral loads (PCR Ct values of 17-
24; see Patients and Methods). Thirty-eight patients
had a single RV, and 14 patients had multiple viruses.
In 3 patients, no RV was detected, but the clinical pic-
ture was typical for RV infection. These patients had
mild respiratory symptoms (rhinorrhea) with no other
cause, and all recovered spontaneously. The distribu-
tion of the various viruses is shown in Table 2.
Primary Endpoint: Allo-LS
Thirty patients were diagnosed with allo-LS
(27.3%), 12 with BOS (10.9%) and 18 with IPS
(16.4%). No patient developed BOOP. One patient
presented with pulmonary hypertension with histolog-
ically proven vasculopathy, with lymphocyte infiltra-
tion that responded to immunosuppressive agents.
We considered this patient to have IPS. For the
30 patients with allo-LS, the median time of onset
was 8 weeks (range, 2-26 weeks) after transplantation.
IPS occurred earlier, with a median time of onset of 7
weeks (range, 2-12 weeks); BOS developed later, after
a median of 16 weeks (range, 10-26 weeks).
In univariate analysis, RV positivity, CB stem cell
graft, and a chemotherapy-based conditioning regi-
men were predictors for the development of allo-LS
(Table 3). In multivariate analysis, only RV positivity
remained a predictor for the development of allo-LS
(HR, 8.37; 95% CI, 1.78-39.43; P 5 .007).
Analyzing the separate endpoints acute allo-LS
(IPS) and chronic allo-LS (BOS) revealed that RV pos-
itivity was the sole predictor for the development of BOS
(HR, 107; 95% CI, 0.9-13,347; P 5 .05). For IPS, RV
positivity (HR, 11.4; 95% CI, 2.61-49.8; P 5 .001),
CB stem cell graft (HR, 4.8; 95% CI, 1.79-12.7; P 5
.002), and nonmalignant indication for transplantation
(HR, 3.3; 95% CI, 1.1-10.2; P 5 .034) were found to
be predictors in univariate analysis. In multivariate
Table 1. Patient Characteristics
RV-Negative RV-Positive P
Age at HSCT, years, median (range) Years 6.0 (0.5-19) 2.6 (0.2-21) NS
Follow-up, weeks, median (range) Weeks 70 (4-230) 57 (4-192) NS
Sex, n (%)
Male 29 (53) 29 (53)
Female 26 (47) 26 (47) NS
Indication, n (%)*
Malignant 31 (56) 25 (46)
Nonmalignant 24 (44) 30 (54) NS
HLA disparity, n (%)†
Matched 39 (71) 30 (54)
Mismatched 16 (29) 25 (46) .076
Number of HSCT, n (%)
First 52 (94) 50 (91)
Second 3 (6) 4 (7)
Third 0 (0) 1 (2) NS
Conditioning, n (%)‡
TBI-based 21 (38) 12 (22)
Chemotherapy-based 34 (67) 43 (78) NS
Donor relationship, n (%)
Family 18 (33) 15 (27)
Unrelated 37 (67) 40 (73) NS
Graft source, n (%)
BM/PBSC 43 (78) 34 (62)
CB§ 12 (22) 21 (38) .061
HSCT indicates hematopoietic stem cell transplantation; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; TBI, total body irradi-
ation; NS, not significant.
*Malignant indications: Acute lymphoblastic leukemia, 34; myelodysplastic syndrome, 9; acute myelogenous leukemia, 8; juvenile myelomonocytic leu-
kemia, 1; lymphoma, 4. Nonmalignant indications: inborn errors of metabolism, 23; immune deficiency, 13; hemophagocytic lymphohistiocytosis, 5; BM
failure, 11; others, 2.
†Matched donor was defined as either 10 of 10 for BM/PBSC grafts molecularly typed or 6 of 6 for CB grafts based on intermediate resolution (HLA-A
and HLA-B on serology and HLA-DR on high resolution).
‡Conditioning regimens: TBI-based (n5 33): Fractionated TBI (3 2  2 Gy) and etoposide 40 mg/kg, 29; thoracoabominal irradiation/cyclophospha-
mide 10 mg/kg)/fludarabine (90 mg/m2), 2; TBI (7 Gy)/etoposide (40 mg/kg), 1; TBI/thiotepa/etoposide, 1. Chemotherapy-based (n5 77): busulfan 480
mg/m2/cyclophosphamide 120 or 200 mg/kg, 46; busulfan 480 mg/m2/cyclophosphamide 120 mg/kg/melphalan 140 mg/m2, 17; busulfan 480 mg/m2/cy-
clophosphamide 120 mg/kg/etoposide 40 mg/kg, 3; busulfan 480 mg/m2/fludarabine 180 mg/m2, 3; busulfan 160 mg/m2/cyclophosphamide 40 mg/kg/flu-
darabine 90 mg/m2, 3; cyclophosphamide 120 mg/kg, 2; treosulfan 42 g/m2/etoposide 40 mg/kg/cyclophosphamide 120 mg/kg, 1; treosulfan 42 g/m2, 1;
none, 1. Patients receiving an unrelated donor graft received serotherapy (thymoglobuline, 37; ATG-fresenius, 16; campath-1H, 3).
§Median cell dose of CB: in nucleated cells, 7.8 (range, 2.7-20.0)  107 cells/kg; in CD34+ cells, 4.5 (range, 1.1-10.0)  105 cells/kg. All CB grafts were
unrelated. One patient received a double CB graft.
Table 2. Viruses Detected by Real-Time RT-PCR
Virus n
Rhinovirus 28
Parainfluenzavirus-3 4
Influenza-A virus 2
Coronavirus 3
Adenovirus 1
Multiple viruses* 14
‘‘Negative’’† 3
*Subdivided: adenovirus/rhinovirus, 4; parainfluenza-3/rhinovirus, 2; hu-
man metapneumovirus/rhinovirus, 2; rhinovirus/adenovirus/parain-
fluenza-3, 2; respiratory syncytial virus/rhinovirus, 1; coronavirus/
parainfluenza-3, 1; coronavirus/adenovirus, 1; coronavirus/rhinovirus, 1.
†Typical clinical symptoms of an URTI with no other explanation.
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8.65; 95% CI, 1.9-38.4; P 5 .005).
The median duration from RV positivity and the
development of allo-LS was 7 weeks (range, 1.2-20
weeks) (Figure 1A). The timing of development of
RV positivity seems to be important as well. Patients
who were RV-positive early after transplantation
(before the median of day 116) had a slightly greater
likelihood of developing allo-LS than those who be-
came RV-positive after day 116 (HR, 2.10; 95% CI,
0.89-5.00 P 5 .089).
Univariate analysis of the influence of HSCT-
associated complications on allo-LS showed that
adenovirus reactivation (OR, 3.86; 95% CI, 1.56-9.5;
P 5 .004) was predictive of allo-LS. aGVHD grade
II-IV in other organs appeared to be a negative predic-
tor (OR, 0.22; 95% CI, 0.061-0.78; P 5 .02). In mul-
tivariate analysis, only aGVHD remained a strong
predictor for preventing allo-LS (OR, 0.1; 95% CI,
0.02-0.47; P 5 .004).
The influence of aGVHD on the development of
allo-LS for the whole group and for the RV-positivepatients is shown in Figure 1B and C. In this study,
aGVHD clearly developed before the onset of allo-
LS. The mean time to onset was 4 weeks for GVHD
(range, 2-15 weeks) and 8 weeks for allo-LS (range,
2-26 weeks). In particular, in the RV-positive group,
aGVHD grade II-IV in another organ was strongly
protective against the development of allo-LS.
Table 3. Univariate Analysis of Predictors for Allo-LS
Allo-LS
Total, n n % HR 95% CI P
Overall 110 30 27.3
Age 0.95 0.88-1.02 .18
Sex
Male 58 15 25.9 1
Female 52 15 28.8 1.03 0.5-2.12 .93
Indication for HSCT
Malignant disorder 56 10 18.0 1
Nonmalignant disorder 54 20 35.7 2.67 0.87-3.97 .11
HLA disparity
Matched 69 17 24.6 1
Mismatched 41 13 31.7 1.14 0.55-2.36 .72
Conditioning
TBI-based 33 4 12.1 1
Chemotherapy-based 77 26 34.0 3.05 1.06-8.75 .04
Donor
Family 33 9 27.3 1
Unrelated 67 21 31.3 1.07 0.49-2.35 .80
Stem cell source
BM/PBSC 67 17 25.4 1
CB 33 13 39.4 2.13 1.03-4.41 .042
RV infection
No 55 3 6.7 1
Yes 55 27 52.9 10.3 3.14-34.3 .00
Recipient CMV serology
Serology-negative 76 19 25 1
Serology-postive 34 11 32.4 1.41 0.59-4.78 .68
HSCT indicates hematopoietic stem cell transplantation; TBI, total body irradiation; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord
blood; CMV, cytomegalovirus.
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viral species, or of the presence of a single virus or mul-
tiple viruses, on the development of allo-LS (data not
shown).
All patients who developed allo-LS were treated
according to the protocol with MP pulse therapy, as
discussed earlier. All patients demonstrated prompt
initial improvement of clinical symptoms.Secondary Endpoints
OS was 72% (80/110) after a median follow up of
66 weeks (range, 4-230 weeks). Cause of death was re-
lapse in 9 patients (8.2%) and nonrelapse mortality in
21 patients (19.1%). Fourteen of the 30 patients with
allo-LS died (47%), all from transplantation-related
causes: 3 from refractory aGVHD, 2 from invasive
fungal infection, 1 from adenovirus disease, 2 from
sudden cardiac death of unknown cause, and 6 from
ongoing lung disease. Univariate analysis identified
adenovirus reactivation (OR, 0.28; 95% CI, 0.08-
0.96; P 5 .043) and the development of allo-LS (OR,
0.25; 95% CI, 0.10-0.61; P 5 .003) as predictors for
lower survival. Relapse had no significant influence
on OS (HR, 1.89; 95% CI, 0.246-14.59; P 5 .54). In
multivariate analysis, only allo-LS remained a predic-
tor in this cohort (OR, 0.29; 95% CI, 0.09-0.94; P 5
.04). The impact of allo-LS on OS is depicted in
Figure 1D.DISCUSSION
Our cohort of 110 patients had a high incidence
(50%) of early RV infection, occurring at a median
of 16 days after HSCT. Rhinovirus infection was the
most commonRV detected. The RV infections usually
had a mild clinical course, and most patients experi-
enced spontaneous recovery within 2 weeks. RV infec-
tion occurring during the first 100 days after HSCT
appeared to be the sole predictor for the development
of acute and chronic allo-LS, which was found in
27.3% of the patients. All patients had recovered
from their initial URTI symptoms before a new epi-
sode of respiratory symptoms occurred, leading to the
diagnosis of allo-LS. The presence of a single RV or
multiple RVs, or the presence of rhinovirus and other
(nonrhinovirus) RVs, was not associatedwith the devel-
opment of allo-LS. Paradoxically, aGVHD had a pro-
tective effect against the development of allo-LS, likely
resulting from the prolonged immunosuppressive ther-
apy in the patients with aGVHD. All of the patients
with allo-LS initially exhibited good clinical response
to MP pulse therapy. The development of allo-LS
was associated with high mortality, however.
A possible weakness of our study is that we changed
our policy on testing for RV during the study period.
In the early phase of the study, we tested NPA samples
for RV only in those patients exhibiting symptoms.
Later in the study period, once the significance of
RV was recognized, weekly surveillance assays were
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Figure 1. RV= Respiratory Virus, allo-LS = alloimmune lungsyndrome, aGVHD = acute graft versus host disease, IPS = Idiopathic Pulmonary Syndrome,
BO = Bronchiolitis Obliterans (Syndrome).
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fied 7 RV-positive patients without symptoms at the
time of sampling; however, all of these patients devel-
oped URTI symptoms within 14 days after positive
sampling, and so these RVs would ultimately have
been detected regardless of the testing policy. Thus,
we believe that we did not miss any RV-positive pa-
tients in the presurveillance period, and that the
change in testing policy had no major impact on our
results (data not shown), the only difference being
that the median time to RV positivity would have
been shorter had we monitored the whole group
routinely.
Three patients with symptoms and a clinical course
typical of viral URTI were considered RV-positive de-
spite negative RV-PCR results. In these patients,
symptoms might have resulted from a virus not detect-
able by our PCR panel. It would be interesting to test
these for more recently identified viruses, such Boca
and Wu/KI. Because of the obvious symptoms and
the fact that other study groups have included similar
patients in their analyses, we decided to do so as well
[10]. Had we considered these patients RV-negative
in our analysis, the results would have been the same
(only 1 of the 3 patients developed allo-LS).We realizethat we may well have missed some mild URTI symp-
toms in the period between discharge and day 1100
and so do not have full data on RV positivity after
discharge from the hospital. No patient who was RV-
PCR–negative on discharge developed allo-LS, how-
ever. Acquisition of RV very early after HSCT appears
to be important for the development of allo-LS; the pa-
tients who were RV- positive within 16 days of HSCT
tended to be more susceptible to allo-LS.
A remark about the definition of IPS is warranted.
In the consensus definition of IPS (established by
a 1997 National Institutes of Health workshop), all in-
fectious agents, including RVs, should be excluded. In
our patients, we observed prolonged shedding of RV
for months, and thus we could not formally diagnose
IPS. In all patients, the initial URTI symptoms disap-
peared spontaneously within 1-2 weeks, however. Sub-
sequently, after a period of at least 14 days without
significant respiratory problems, symptoms of hypoxia
and/or airway obstruction recurred. We believe that
this represents not a direct progression of viral infec-
tion, but rather a combination of several factors in
which alloreactivity (triggered by tissue damage be-
cause of persistent viral infection) plays a pivotal
role. Therefore, we chose to define IPS as discussed
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identified by PCR as was done in this study. Moreover,
the formal definition of IPS was promulgated in an era
when molecular diagnosis of RV was not yet available.
We hypothesize that RVs may contribute to the
pathogenesis of any allo-LS as follows. The RV dam-
ages the respiratory epithelium, causing an inflamma-
tory response at the time of immune recovery.
Normally IPS and BOS/BOOP are viewed as distinct
clinical entities, and so we first studied them sepa-
rately. Because we noted the same strong associations
among RV positivity, GVHD, and OS in the 2 groups,
we combined both IPS and BOS/BOOP in subsequent
analyses.
We also combined BM and PBSC sources in our
analysis. It would be interesting to evaluate patients
receiving PBSCs as a separate group, because of their
apparent higher risk of chronic GVHD (cGVHD).
The small number of patients our cohort who re-
ceived PBSCs (n 5 7) precludes meaningful analysis,
however.
Numerous studies have explored the incidence and
outcome of both nosocomial and community-acquired
RV infections after HSCT [7-16]. Reported incidence
varies from 1% to 56%. This wide range of incidence
can be explained by differences among studies in the
definition of RV infection, the period of monitoring
for RV infection (eg, inpatients/outpatients, seasonal
influence), and sensitivity of the analysis methods
used. In our cohort, the high incidence of RV URTI
(50%) might be attributed to our close monitoring
for respiratory symptoms and performance of RT-
PCR surveillance assays. In addition, nosocomial RV
infections were frequently observed, and genotyping
studies suggested that these had spread throughout
the ward during the study period, also contributing
to the relatively high incidence (data not shown).
Literature data on the morbidity associated with
RV infection afterHSCT are conflicting. Some groups
found no progression of viral URTI to LRTI in pa-
tients after HSCT [10,15], whereas others reported
progression in up to 58% of patients [7,8,11,13,16].
In our cohort, we found no direct progression to
LRTI. Almost all patients had mild URTI symptoms
and recovered spontaneously. Themedian day of onset
of RV infection was only 16 days in our cohort, com-
pared with at least 60 days in previous studies. Progres-
sion to LRTI might be expected in patients with RV
infection early after transplantation, because of poor
immune status, but this was not seen. In our opinion,
it is more likely that the moment of immune recovery
defines the onset of symptoms. What we define as IPS
in this study (ie, symptoms after a period of quiescent
RV infection) might have been reported in other stud-
ies as progressive viral pneumonia, with symptoms oc-
curring at the onset of RV infection later after HSCT,
when some immune recovery has already occurred.The reported incidence of IPS after HSCT ranges
from 2% to 15% of patients [2,4,25,26], and that of
BOS ranges from 0% to 26% [1,4,27,28]. Most re-
ported data are from adult studies. The combined inci-
dence of allo-LS in our cohort of 27.3% is comparable
to that reported in the literature. Our incidence of IPS
is relatively high, most likely because our cohort in-
cluded a high number of early RV-positive patients.
We found a strong association betweenRV infection
and the development of allo-LS. To the best of our
knowledge, this is the first report of such a strong asso-
ciation between RV infection and life-threatening allo-
LS. Earlier, Erard et al. [17] described a relationship be-
tween RV infection during the first 100 days after
HSCT and a decline in airflow leading to increased
overall mortality. The decline in airflow was detected
immediately after infection and did not return to base-
line values, suggesting sustained airway inflammation
leading to permanent loss of lung function. Pulmonary
disease was much more severe in our cohort compared
with the cohort of Erard et al. [17]. This discrepancy
can be explained by the early moment of RV infection,
when immune recovery has not yet occurred and the
persistent RV likely causes more tissue damage, ulti-
mately resulting in a stronger inflammatory response.
The absence of immunity at the time of primary RV in-
fection also might explain the absence of an immediate
decline in clinical lung function. Pulmonary function de-
teriorated only after at least 2 weeks after RV infection,
when the first signs of immune recovery were evident. It
would be interesting to routinely perform PFTs earlier
afterHSCT, but for reasons of hygiene and patient com-
fort, we decided not to do this in the present study.
Most previous studies have found an association
between the presence of GVHD and the development
of allo-LS [1,2,25,29]. In those studies, aGVHD was
associated with IPS, but other risk factors, including
conditioning regimen and infection, might have been
involved as well. cGVHD is considered an important
risk factor for BOS in adults. Alloreactive T cells, in
the context of aGVHD or cGVHD, play an important
role in BOS [29]. BOS is also seen in the absence of
cGVHD in 7%-18% of patients, however [27]. This
percentage may be different in children, who are less
susceptible to cGVHD [30]. Our finding that aGVHD
grade II-IV in other organs has a protective effect on
the development of allo-LS does not necessarily con-
tradict these results. Like aGVHD, allo-LS is a mani-
festation of alloimmunity. We speculate that the
apparent protective effect of aGVHD reflects the in-
fluence on alloreactive T cells of immunosuppressive
agents used to treat aGVHD grade II-IV. None of
our patients had lung involvement at the onset of
aGVHD. This may be because the lungs are less sus-
ceptible to acute alloreactivity than the classic target
organs of gut, liver, and skin. This is also reflected by
the fact that the median time to allo-LS was longer
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All patients who developed allo-LS did so during taper-
ing of immunosuppressive therapy or after this therapy
had been stopped. All of the patients with aGVHD
where on prolonged immunosuppressive therapy (in-
cluding steroids) and thus likely had less chance to de-
velop alloimmunity in the lungs. In other words, the
RV-positive patients who did not develop allo-LS
had significantly greater immune suppression than
the RV-positive patients who did develop allo-LS
(data not shown). This effect of immunosuppressive
therapy on the development of allo-LS is in line with
previous findings [31]. Regarding cGVHD, in contrast
to other studies, in our cohort, only 1 of 12 patients
(11%) with BOS had signs of cGVHD in other organs.
Our finding of no association between cGVHD and
BOS/BOOP might be because of the generally low in-
cidence of cGVHD in the pediatric HSCT population.
This, together with the fact that viral infections are
more frequent in childhood, might make the respira-
tory epithelium a preferential target for chronic allor-
eactivity, at least in this pediatric cohort. No
protective effect of cGVHD on the development of
allo-LS was noted, most likely because cGVHD
(mainly the limited form) was not treated with systemic
immunosuppressive agents (eg, steroids).
A similar association between RV infection and
allo-LS has been reported after lung transplantation.
A recent prospective cohort study in 100 lung trans-
plant recipients clearly showed had significantly
more acute or chronic rejection episodes in patients
with an RV infection occurring within 100 days post-
transplantation [18]. BOS occurring after lung trans-
plantation is considered a manifestation of allograft
rejection [32,33] because of an alloimmune process.
Some animal models of lung transplantation have
demonstrated an association between the presence of
RV and the development of BOS exclusively in the
allogeneic transplantation setting [34]. These results
are in line with the association between RV infection
and allo-LS seen in our HSCT population, and
strongly support the hypothesis that airway damage
from an RV infection alone does not lead to severe
problems, but triggers alloimmunity. Because of this
strong association, the current practice in lung trans-
plantation is to increase immunosuppression by
adding steroids in the presence of an RV infection
posttransplantation, to avoid rejection (personal com-
munication Lung transplantation programm UMC
Groningen and UMC Utrecht, 2007). This practice
has led to a decreased graft rejection rate.
Increasing immunosuppression solely because of
the presence of a RV may sound paradoxical, possibly
predisposing the patient to other potentially life-
threatening complications, but it is supported by our
observation that patients with RV infection early after
HSCT were less vulnerable to allo-LS when receivingimmunosuppression for aGVHD. At present, we
cannot predict which RV-positive patients are actually
at risk for developing allo-LS. Early recognition of the
disease by the detection of biomarkers associated with
lung damage and the development of allo-LS, or the
identification of certain risk groups by studying the
genetic polymorphisms of innate immunity in these
patients, might be of additional value to fine-tune the
initiation or adjustment of immunosuppressive
therapy in the HSCT setting.
In conclusion, we have shown a clear relation
between early RV infection and the development of
allo-LS in pediatric HSCT recipients. Tissue damage
because of the persistence of RV in the lung might be
a trigger for the development of allo-LS. aGVHD,
but more likely greater immunosuppression because of
the aGVHD, appears to protect for allo-LS.These find-
ings suggest that prevention of RV infections early after
HSCT is of utmost importance. In addition, prolonged
immune suppression in transplant recipients with anRV
infection might prevent development of allo-LS, in
analogy with current practice in lung transplantation.AUTHORSHIP STATEMENT
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